Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- Rolling with the punchlines: Lessons in resilience from a wheelchair comedian
- Oral ALS treatment lowers toxic protein levels, extends survival
- Ex-NFL running back says he ‘chose to fight’ after his ALS diagnosis
- New ALS treatment enters human testing in global program
- Accessible travel granted my late husband normalcy, independence